Jack Schuler Net Worth

The estimated Net Worth of Jack W Schuler is at least $52.4 Million dollars as of 28 June 2024. Mr. Schuler owns over 4,737 units of Accelerate Diagnostics Inc stock worth over $32,562 and over the last 21 years he sold AXDX stock worth over $52,236,792. In addition, he makes $133,904 as Independent Director at Accelerate Diagnostics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Schuler AXDX stock SEC Form 4 insiders trading

Jack has made over 213 trades of the Accelerate Diagnostics Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently he exercised 4,737 units of AXDX stock worth $7,627 on 28 June 2024.

The largest trade he's ever made was buying 8,695,652 units of Accelerate Diagnostics Inc stock on 21 November 2022 worth over $10,000,000. On average, Jack trades about 228,303 units every 15 days since 2003. As of 28 June 2024 he still owns at least 20,225 units of Accelerate Diagnostics Inc stock.

You can see the complete history of Mr. Schuler stock trades at the bottom of the page.

Jack Schuler biography

Jack W. Schuler serves as Independent Director of the Company. since June 26, 2012. Mr. Schuler is a founding partner of Crabtree Partners, a private equity investment firm. Mr. Schuler served as a director of Ventana Medical Systems, Inc. from 1991 and as Chairman of the Board from 1995 until Ventana’s acquisition by Roche in 2008. Mr. Schuler served as a director of Stericycle, Inc. (NASDAQ: SRCL) from March 1990 to May 2018, formerly serving as Chairman of the Board. Prior to his retirement, Mr. Schuler held various executive positions at Abbott Laboratories from December 1972 through August 1989, most recently serving as President and Chief Operating Officer. He is currently a director of Quidel Corporation (NASDAQ: QDEL). Mr. Schuler holds a B.S. in Mechanical Engineering from Tufts University and an M.B.A. from Stanford University.

What is the salary of Jack Schuler?

As the Independent Director of Accelerate Diagnostics Inc, the total compensation of Jack Schuler at Accelerate Diagnostics Inc is $133,904. There are 8 executives at Accelerate Diagnostics Inc getting paid more, with John Phillips having the highest compensation of $12,300,900.

How old is Jack Schuler?

Jack Schuler is 79, he's been the Independent Director of Accelerate Diagnostics Inc since 2012. There are no older and 14 younger executives at Accelerate Diagnostics Inc.

What's Jack Schuler's mailing address?

Jack's mailing address filed with the SEC is C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON, AZ, 85714.

Insiders trading at Accelerate Diagnostics Inc

Over the last 12 years, insiders at Accelerate Diagnostics Inc have traded over $26,833,308 worth of Accelerate Diagnostics Inc stock and bought 16,366,880 units worth $209,384,489 . The most active insiders traders include Jack W Schuler, Larry N Feinberg und Matthew Strobeck. On average, Accelerate Diagnostics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $132,645. The most recent stock trade was executed by Hany Massarany on 28 June 2024, trading 4,737 units of AXDX stock currently worth $7,627.

What does Accelerate Diagnostics Inc do?

accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.

Complete history of Mr. Schuler stock trades at Accelerate Diagnostics Inc, Biolase Inc, Neos Therapeutics Inc, QuidelOrtho, Soleno Therapeutics Inc, Stericycle, Vermillion, Yield10 Bioscience Inc und Biodesix Inc

Accelerate Diagnostics Inc executives and stock owners

Accelerate Diagnostics Inc executives and other stock owners filed with the SEC include:

• John Phillips,
  Chief Executive Officer, Chief Operating Officer, Director
• Steve Reichling,
  Chief Financial Officer
• Jack Phillips,
  CEO, Pres & Director
• Ron Price,
  Senior Vice President, Head of Commercial Operations, Americas
• Roland Diggelmann,
  Independent Director
• Louise Francesconi,
  Independent Director
• Steve Reichling,
  CFO & Chief Accounting Officer
• Ron Price,
  Chief Commercial Officer of Americas
• Charles Watts,
  Independent Director
• Frank ten Brink,
  Independent Director
• Matthew Strobeck,
  Independent Director
• Jack Schuler,
  Independent Director
• Mark Miller,
  Independent Director
• Thomas Brown,
  Independent Director
• John Patience,
  Independent Chairman of the Board
• Nedal Safwat,
  Chief Strategy Officer
• Dr. Lawrence Mertz,
  Sr. VP and Head of R&D
• John Meduri,
  Chief Strategy Officer
• Laura Costa,
  Sr. VP & Head of Global Customer Support
• Cherif Bousselham,
  Sr. VP & Head of Sales - EMEA
• Gretchen Strohminger,
  Sr. VP and Head of HR & Culture
• Michael Bridge,
  Sr. VP, Gen. Counsel & Sec.
• Laura Pierson,
  Investor Relations Officer
• Larry N Feinberg,
  10% owner
• Pete Bantock,
  CHIEF COMMERCIAL OFFICER
• Lawrence Mehren,
  PRESIDENT AND CEO
• Marran H. Ogilvie,
  Director
• Jennifer Regan,
  Director
• Mark S. Black,
  Director
• Ventures, Llc Abeja,
  10% owner
• Romney Humphries,
  Chief Scientific Officer
• Larry Michael Mertz,
  Chief Technology Officer
• Hany Massarany,
  Director
• Jack Phillips,
  Chief Executive Officer
• Wayne Burris,
  Director
• David Patience,
  Chief Financial Officer